Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer.

Purpose The aim of this retrospective study was to evaluate the tolerance and early as well as late toxicity of high dose rate brachytherapy (HDRBT) boost combined with interstitial hyperthermia (IHT) in patients treated for prostate cancer. Material and methods Between January 2011 and June 2013 76 patients diagnosed with prostate cancer received treatment consisting of external beam radiotherapy (EBRT), followed by a HDRBT boost combined with IHT. IHT was performed before each brachytherapy fraction.

Does microwave interstitial hyperthermia prior to high-dose-rate brachytherapy change prostate volume or therapy plan parameters?

Purpose: In this prospective preliminary study we evaluated changes of prostate volume and changes of brachytherapy treatment plan parameters due to interstitial hyperthermia (IHT) applied prior to high-dose-rate brachytherapy (HDRBT), compared to our standard HDRBT procedure.

Material And Methods: In a group of 60 consecutive patients with prostate adenocarcinoma, 30 were treated with HDRBT alone and 30 with IHT preceding HDRBT. Prior to catheter implantation, a 'virtual' treatment plan (VP) was complied, a 'live' plan (LP) was prepared before patient irradiation, and a 'post' plan (PP) was drawn up after completing the irradiation procedure.

High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.

Purpose: We report a single-institution retrospective analysis of the outcomes, disease control, and toxicity of high-dose-rate (HDR) brachytherapy used as the only treatment modality (monotherapy) for localized prostate cancer.

Methods: Between 2006 and 2012, 77 patients with diagnosed prostate cancer were treated with HDR brachytherapy as a monotherapy. The prescribed dose was 45 Gy in three separate implants 21 days apart, with single fraction per implant.